| Ytd | -36.65% | |
| 1y | -33.75% |
| Open | 3.46 | Prev Close | 3.56 | Low | 3.46 | High | 3.51 | Mkt Cap | 6.67M |
| Vol | 3.89K | Avg Vol | 27.81K | EPS | -16.51 | P/E | N/A | Forward P/E | -0.40 |
| Beta | 1.09 | Short Ratio | 0.54 | Inst. Own | 58.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 3.83 | 200-d Avg | 4.69 | 1yr Est | 1.75 |
BOLT News
Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular sess
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.57 per share versus the Zacks
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.57) per share which missed the a
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clini
VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:B
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Bolt Biotherapeutics (NASD
HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.31 per share versus the Zacks
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.31) per share which missed the a
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinic
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) was the recipient of a significant growt
HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.84 per share versus the Zacks
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(3.84) per share which beat the ana
REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clin
Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) ar
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clini
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) was the target of a large decrease in sh
Acumen Pharmaceuticals (NASDAQ: ABOS - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get
https://x.com/PatentGrants/status/1998150771544928598?s=20
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.72 per share versus the Zacks
Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance o
Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely
Toronto, Ontario--(Newsfile Corp. - Le 20 octobre/October 2025) - Bolt Metals Corp. has announced a
HC Wainwright & Co. analyst Robert Burns assumes Bolt Biotherapeutics (NASDAQ:BOLT) with a Bu
REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clini
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.46 per share versus the Zacks
REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clini
Friday's session saw 112 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
On Tuesday, 210 companies reached new 52-week lows.
On Wednesday, 152 stocks made new 52-week lows.
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday&#
On Friday, 1043 companies hit new 52-week lows.
During Wednesday's trading, 435 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.